Literature DB >> 24696612

Myofibroblastic cell activation and neovascularization predict native liver survival and development of esophageal varices in biliary atresia.

Janne S Suominen1, Hanna Lampela1, Päivi Heikkilä1, Jouko Lohi1, Hannu Jalanko1, Mikko P Pakarinen1.   

Abstract

AIM: To study the relation between collagen 1, α-smooth muscle actin (α-SMA) and CD34 expression and the most essential portoenterostomy (PE) outcomes.
METHODS: Liver specimens were obtained at PE from 33 biliary atresia (BA) patients for immunohistochemical analysis of collagen 1, α-SMA and CD34. Liver biopsies from 35 organ donors were used as controls. Expression patterns were related to clinical data including age at PE, serum total and conjugated bilirubin concentration at the time of PE and during follow-up, incidence of esophageal varices in follow-up upper gastrointestinal endoscopies, and native liver survival as well as to detailed histopathological findings.
RESULTS: Collagen 1 (16.4% vs 4.5%, P < 0.0001), α-SMA (17.9% vs 4.6%, P < 0.0001) and CD34 (4.9% vs 3.8%, P = 0.017) were markedly overexpressed in BA patients compared with controls. Patients who underwent liver transplantation by age of two years had significantly higher expression of collagen 1 (18.6% vs 13.7%, P = 0.024), α-SMA (20.4% vs 15.4%, P = 0.009) and CD34 (5.9% vs 4.0%, P = 0.029) at PE compared with native liver survivors. CD34-positive microvessels were identified in the centrizonal region close to central vein in every BA patient. In majority of BA cases (56%) neovascularization was frequent as CD34-positive microvessels were observed in over half of the hepatic lobules. In controls, the CD34-positive microvessels were rare as they were completely absent in 40 % and were found in less than 5 % of the hepatic lobules in the rest. The difference between BA patients and controls was significant (P < 0.0001). Patients who developed esophageal varices by two years had significantly higher expression of CD34 at PE compared with patients without varices (5.6% vs 4.0%, P = 0.019). Expression of α-SMA (r = 0.758, P < 0.0001) and collagen 1 (r = 0.474, P = 0.016), and the amount of CD34-positive microvessels (r = 0.356, P = 0.047) were related to patient age at PE.
CONCLUSION: Hepatic myofibroblastic cell activation, fibrogenesis and neovascularization are enhanced in BA, progress with increasing PE age and relate to native liver survival and development of esophageal varices.

Entities:  

Keywords:  Biliary atresia; CD34; Collagen 1; Liver fibrosis; Neovascularization; α-smooth muscle actin

Mesh:

Substances:

Year:  2014        PMID: 24696612      PMCID: PMC3964401          DOI: 10.3748/wjg.v20.i12.3312

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  30 in total

1.  The role of CK7, Ki-67, CD34 and vimentin in the differentiation between biliary atresia and idiopathic neonatal hepatitis in Egyptian cholestatic neonates.

Authors:  Hayam Abdel Samie Aiad; Mona Abdel Halim Kandil; Rehab Monir Samaka; Mervat Mahmoud Sultan; Mohamed Tawfik Badr; Gammal Eldin Mahmoud Nada
Journal:  APMIS       Date:  2012-01-12       Impact factor: 3.205

2.  RRAS: A key regulator and an important prognostic biomarker in biliary atresia.

Authors:  Rui Zhao; Hao Li; Chun Shen; Shan Zheng
Journal:  World J Gastroenterol       Date:  2011-02-14       Impact factor: 5.742

Review 3.  Histological grading and staging of chronic hepatitis.

Authors:  K Ishak; A Baptista; L Bianchi; F Callea; J De Groote; F Gudat; H Denk; V Desmet; G Korb; R N MacSween
Journal:  J Hepatol       Date:  1995-06       Impact factor: 25.083

4.  Endoscopic surveillance and primary prophylaxis sclerotherapy of esophageal varices in biliary atresia.

Authors:  Hanna Lampela; Silja Kosola; Antti Koivusalo; Jouni Lauronen; Hannu Jalanko; Risto Rintala; Mikko P Pakarinen
Journal:  J Pediatr Gastroenterol Nutr       Date:  2012-11       Impact factor: 2.839

5.  National centralization of biliary atresia care to an assigned multidisciplinary team provides high-quality outcomes.

Authors:  Hanna Lampela; Annukka Ritvanen; Silja Kosola; Antti Koivusalo; Risto Rintala; Hannu Jalanko; Mikko Pakarinen
Journal:  Scand J Gastroenterol       Date:  2012-01       Impact factor: 2.423

6.  Contribution of hepatic parenchymal and nonparenchymal cells to hepatic fibrogenesis in biliary atresia.

Authors:  G A Ramm; V G Nair; K R Bridle; R W Shepherd; D H Crawford
Journal:  Am J Pathol       Date:  1998-08       Impact factor: 4.307

Review 7.  Biliary atresia: recent progress.

Authors:  Mikelle D Bassett; Karen F Murray
Journal:  J Clin Gastroenterol       Date:  2008-07       Impact factor: 3.062

8.  Increased expression of intercellular adhesion molecules in biliary atresia.

Authors:  P Dillon; D Belchis; T Tracy; R Cilley; L Hafer; T Krummel
Journal:  Am J Pathol       Date:  1994-08       Impact factor: 4.307

Review 9.  Biliary atresia.

Authors:  Jane L Hartley; Mark Davenport; Deirdre A Kelly
Journal:  Lancet       Date:  2009-11-14       Impact factor: 79.321

10.  Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice.

Authors:  Mercedes Fernandez; Francesco Vizzutti; Juan Carlos Garcia-Pagan; Juan Rodes; Jaime Bosch
Journal:  Gastroenterology       Date:  2004-03       Impact factor: 22.682

View more
  2 in total

Review 1.  Early and Peri-operative Prognostic Indicators in Infants Undergoing Hepatic Portoenterostomy for Biliary Atresia: a Review.

Authors:  Robert N Lopez; Chee Y Ooi; Usha Krishnan
Journal:  Curr Gastroenterol Rep       Date:  2017-04

2.  Expression of 6 Biomarkers in Liver Grafts After Pediatric Liver Transplantation: Correlations with Histology, Biochemistry, and Outcome.

Authors:  Silja H Voutilainen; Silja K Kosola; Jouko Lohi; Aino Mutka; Timo Jahnukainen; Mikko Pakarinen; Hannu Jalanko
Journal:  Ann Transplant       Date:  2020-10-16       Impact factor: 1.530

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.